Sangamo Therapeutics, Inc. – NASDAQ:SGMO
Sangamo Therapeutics stock price today
$0.555
-2.00
-78.32%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 3 days
Sangamo Therapeutics stock price monthly change
+462.88%
month
Sangamo Therapeutics stock price quarterly change
+462.88%
quarter
Sangamo Therapeutics stock price yearly change
+376.72%
year
Sangamo Therapeutics key metrics
Market Cap | 522.66M |
Enterprise value | 163.88M |
P/E | -1.2 |
EV/Sales | 1.47 |
EV/EBITDA | -0.98 |
Price/Sales | 2.02 |
Price/Book | 0.76 |
PEG ratio | 0.73 |
EPS | -1.86 |
Revenue | 18.75M |
EBITDA | -133.73M |
Income | -328.05M |
Revenue Q/Q | -99.69% |
Revenue Y/Y | -92.21% |
Profit margin | -172.76% |
Oper. margin | -180.85% |
Gross margin | 26.4% |
EBIT margin | -180.85% |
EBITDA margin | -713.04% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeSangamo Therapeutics stock price history
Sangamo Therapeutics stock forecast
Sangamo Therapeutics financial statements
| Jun 2023 | 6.83M | -114.50M | -1675.29% |
|---|---|---|---|
| Sep 2023 | 9.39M | -104.16M | -1108.35% |
| Dec 2023 | 2.04M | -60.29M | -2952.79% |
| Mar 2024 | 481K | -49.08M | -10205.61% |
| Sep 2025 | 7.75M | -15.39M | -198.63% |
|---|---|---|---|
| Oct 2025 | 7.75M | -13.82M | -178.4% |
| Dec 2025 | 34.2M | -5.41M | -15.82% |
| Mar 2026 | 658.25K | -23.39M | -3553.4% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 325074000 | 91.43M | 28.13% |
|---|---|---|---|
| Sep 2023 | 219697000 | 84.77M | 38.59% |
| Dec 2023 | 165320000 | 82.43M | 49.86% |
| Mar 2024 | 128961000 | 72.26M | 56.04% |
| Jun 2023 | -60.71M | 42.46M | 6.51M |
|---|---|---|---|
| Sep 2023 | -47.29M | 37.62M | -100K |
| Dec 2023 | -50.53M | 37.70M | 167K |
| Mar 2024 | -48.66M | 35.84M | 22.12M |
Sangamo Therapeutics alternative data
Gene Editing
| 4 Aug 2024 | 21 |
|---|---|
| 11 Aug 2024 | 21 |
| 18 Aug 2024 | 20 |
| 25 Aug 2024 | 24 |
| 1 Sep 2024 | 28 |
| 8 Sep 2024 | 28 |
| 15 Sep 2024 | 34 |
| 22 Sep 2024 | 33 |
| 29 Sep 2024 | 30 |
| 6 Oct 2024 | 50 |
| 13 Oct 2024 | 40 |
| 20 Oct 2024 | 31 |
| 27 Oct 2024 | 35 |
| 3 Nov 2024 | 29 |
| 10 Nov 2024 | 34 |
| 17 Nov 2024 | 37 |
| 24 Nov 2024 | 33 |
| 1 Dec 2024 | 40 |
| 8 Dec 2024 | 47 |
| 15 Dec 2024 | 38 |
Gene Editing Companies
| 25 Aug 2024 | 22 | 8 | 33 | 17 |
|---|---|---|---|---|
| 1 Sep 2024 | 11 | 7 | 21 | 17 |
| 8 Sep 2024 | 8 | 6 | 27 | 25 |
| 15 Sep 2024 | 9 | 4 | 27 | 15 |
| 22 Sep 2024 | 10 | 3 | 26 | 13 |
| 29 Sep 2024 | 10 | 4 | 26 | 16 |
| 6 Oct 2024 | 9 | 4 | 25 | 27 |
| 13 Oct 2024 | 6 | 3 | 21 | 15 |
| 20 Oct 2024 | 11 | 0 | 20 | 19 |
| 27 Oct 2024 | 14 | 5 | 49 | 20 |
| 3 Nov 2024 | 13 | 5 | 36 | 24 |
| 10 Nov 2024 | 12 | 4 | 39 | 20 |
| 17 Nov 2024 | 6 | 4 | 29 | 17 |
| 24 Nov 2024 | 10 | 4 | 23 | 17 |
| 1 Dec 2024 | 10 | 4 | 27 | 21 |
| 8 Dec 2024 | 8 | 6 | 25 | 28 |
| 15 Dec 2024 | 8 | 3 | 34 | 29 |
| 22 Dec 2024 | 11 | 4 | 47 | 41 |
| 29 Dec 2024 | 40 | 16 | 65 | 41 |
| 5 Jan 2025 | 27 | 9 | 55 | 43 |
Types of Gene Editing
| 5 Mar 2023 | 0 | 11 | 20 |
|---|---|---|---|
| 12 Mar 2023 | 0 | 12 | 18 |
| 19 Mar 2023 | 1 | 9 | 19 |
| 26 Mar 2023 | 0 | 9 | 21 |
| 2 Apr 2023 | 1 | 9 | 22 |
| 9 Apr 2023 | 0 | 21 | 31 |
| 16 Apr 2023 | 1 | 16 | 24 |
| 23 Apr 2023 | 1 | 13 | 23 |
| 30 Apr 2023 | 1 | 11 | 22 |
| 7 May 2023 | 0 | 11 | 61 |
| 14 May 2023 | 1 | 13 | 38 |
| 21 May 2023 | 1 | 9 | 30 |
| 28 May 2023 | 0 | 10 | 29 |
| 4 Jun 2023 | 1 | 10 | 24 |
| 11 Jun 2023 | 1 | 10 | 29 |
| 18 Jun 2023 | 1 | 10 | 29 |
| 25 Jun 2023 | 1 | 11 | 29 |
| 2 Jul 2023 | 1 | 9 | 34 |
| 9 Jul 2023 | 1 | 19 | 40 |
| 16 Jul 2023 | 1 | 100 | 34 |
Numbers represent search interest relative to the highest point on the chart for the given region and time.
A value of 100 is the peak popularity for the term.
A value of 50 means that the term is half as popular.
A score of 0 means there was not enough data for this term.
What is job openings count?
| Aug 2023 | 16 |
|---|---|
| Sep 2023 | 15 |
| Oct 2023 | 9 |
| Nov 2023 | 4 |
| Dec 2023 | 2 |
| Jan 2024 | 0 |
| Feb 2024 | 1 |
| Apr 2024 | 0 |
| May 2024 | 0 |
| Jun 2024 | 1 |
| Jul 2024 | 0 |
| Aug 2023 | 478 |
|---|---|
| Sep 2023 | 478 |
| Oct 2023 | 478 |
| Nov 2023 | 478 |
| Dec 2023 | 478 |
| Jan 2024 | 478 |
| Feb 2024 | 478 |
| Mar 2024 | 405 |
| Apr 2024 | 405 |
| May 2024 | 405 |
| Jun 2024 | 405 |
| Jul 2024 | 405 |
Sangamo Therapeutics other data
38.45%
-27.23%
of SGMO is owned by hedge funds
122
-53
59.35M
-44.45M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Sep 2023 | 0 | 6000000 |
| Patent |
|---|
Application Filling date: 10 Jan 2022 Issue date: 1 Sep 2022 |
Grant Filling date: 17 Apr 2019 Issue date: 23 Aug 2022 |
Grant Utility: Engineered target specific nucleases Filling date: 8 Feb 2019 Issue date: 2 Aug 2022 |
Application Filling date: 22 Jul 2021 Issue date: 30 Jun 2022 |
Application Filling date: 23 Feb 2022 Issue date: 9 Jun 2022 |
Application Filling date: 4 Oct 2021 Issue date: 12 May 2022 |
Grant Filling date: 29 Apr 2020 Issue date: 26 Apr 2022 |
Grant Filling date: 12 Nov 2019 Issue date: 29 Mar 2022 |
Application Filling date: 15 Jan 2020 Issue date: 3 Mar 2022 |
Grant Filling date: 12 Jul 2018 Issue date: 1 Feb 2022 |
| Quarter | Transcript |
|---|---|
| Q1 2024 9 May 2024 | Q1 2024 Earnings Call Transcript |
| Q3 2023 2 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 8 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Q1 2023 27 Apr 2023 | Q1 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
Dr. Alexander D. Macrae Ch.B, M.B., MRCP, Ph.D. (1963) Chief Executive Officer, Pres & Director | $1,200,000 |
Dr. R. Andrew Ramelmeier Ph.D. (1962) Executive Vice President of Technical Operations | $675,480 |
Mr. D. Mark McClung (1963) Executive Vice President & Chief Operating Officer | $568,000 |
Voyager: Crossing The Blood-Brain Barrier, Competitors, And Investment Relevance
Sangamo: Pipeline Expansion Via Partnership And Internal ST-503 Development
Sangamo Therapeutics: Recent Updates Bolster My Long-Term Conviction
Sangamo: Hemophilia A Program With Pfizer Key To Success
Biopharma Exposure In SVB Financial Group And Investor Strategy
Sangamo Therapeutics: Ready To Dust Off My Dormant Position Ahead Of A Pivotal 2023
Athersys: Is Big Pharma Sleeping At The Wheel?
Crispr: Elucidating And Forecasting Key Developments
Sangamo Therapeutics: Strong Fabry Data Puts Them In The Lead
-
What's the price of Sangamo Therapeutics stock today?
One share of Sangamo Therapeutics stock can currently be purchased for approximately $0.56.
-
When is Sangamo Therapeutics's next earnings date?
Unfortunately, Sangamo Therapeutics's (SGMO) next earnings date is currently unknown.
-
Does Sangamo Therapeutics pay dividends?
No, Sangamo Therapeutics does not pay dividends.
-
How much money does Sangamo Therapeutics make?
Sangamo Therapeutics has a market capitalization of 522.66M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 58.34% to 176.23M US dollars.
-
What is Sangamo Therapeutics's stock symbol?
Sangamo Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "SGMO".
-
What is Sangamo Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Sangamo Therapeutics?
Shares of Sangamo Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Sangamo Therapeutics's key executives?
Sangamo Therapeutics's management team includes the following people:
- Dr. Alexander D. Macrae Ch.B, M.B., MRCP, Ph.D. Chief Executive Officer, Pres & Director(age: 62, pay: $1,200,000)
- Dr. R. Andrew Ramelmeier Ph.D. Executive Vice President of Technical Operations(age: 63, pay: $675,480)
- Mr. D. Mark McClung Executive Vice President & Chief Operating Officer(age: 62, pay: $568,000)
-
How many employees does Sangamo Therapeutics have?
As Jul 2024, Sangamo Therapeutics employs 405 workers.
-
When Sangamo Therapeutics went public?
Sangamo Therapeutics, Inc. is publicly traded company for more then 25 years since IPO on 6 Apr 2000.
-
What is Sangamo Therapeutics's official website?
The official website for Sangamo Therapeutics is sangamo.com.
-
Where are Sangamo Therapeutics's headquarters?
Sangamo Therapeutics is headquartered at 501 Canal Blvd, Brisbane California, CALIFORNIA.
-
How can i contact Sangamo Therapeutics?
Sangamo Therapeutics's mailing address is 501 Canal Blvd, Brisbane California, CALIFORNIA and company can be reached via phone at +51 09706000.
Sangamo Therapeutics company profile:
Sangamo Therapeutics, Inc.
sangamo.comExchange:
NASDAQ
Full time employees:
405
Industry:
Biotechnology
Sector:
Healthcare
Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucleases, which are proteins used in modifying DNA sequences by adding or knocking out specific genes; and ZFP transcription factors proteins used in increasing or decreasing gene expression. It develops SB-525, which is in Phase III AFFINE clinical trial for the treatment of hemophilia A; ST-920, a gene therapy, which is in Phase I/II STAAR clinical trials for the treatment of Fabry disease; and SAR445136, a cell therapy, which is in Phase I/II PRECIZN-1 clinical trials for the treatment of sickle cell disease. The company also develops TX200, chimeric antigen receptor for the treatment of HLA-A2 mismatched kidney transplant rejection; KITE-037, a cell therapy for the treatment of cancer; ST-501 for the treatment of tauopathies; and ST-502 for the treatment of synucleinopathies, including Parkinson's disease and neuromuscular disease. It has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Brisbane, California.
501 Canal Blvd
Brisbane California, CALIFORNIA 94005
Brisbane California, CALIFORNIA 94005
CIK: 0001001233
ISIN: US8006771062
CUSIP: 800677106
